Pneumococcal polysaccharide-protein CRM197 conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule

scientific article published on 01 March 2011

Pneumococcal polysaccharide-protein CRM197 conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1586/ERV.11.11
P698PubMed publication ID21434795

P2093author name stringMark A Fletcher
Bernard Fritzell
P433issue3
P921main subjectpolysaccharideQ134219
P304page(s)263-290
P577publication date2011-03-01
P1433published inExpert Review of VaccinesQ15756339
P1476titlePneumococcal polysaccharide-protein CRM197 conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule
P478volume10

Reverse relations

cites work (P2860)
Q54235847A toddler PCV booster dose following 3 infancy priming doses increases circulating serotype-specific IGG levels but does not increase protection against carriage.
Q92968782Delivering vaccines for the prevention of pneumonia - programmatic and financial issues
Q82081130Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants
Q38443063Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose
Q35089126Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination
Q84344058The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial

Search more.